Human IL-1 RII Antibody Summary
Phe14-Glu343 (Ser56Gly and Glu297Gly)
Accession # P27930
under non-reducing conditions only
Human IL-1 RII Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IL‑1 RII Inhibition of IL‑1 beta /IL‑1F2-dependent Cell Proliferation and Neutralization by Human IL‑1 RII Antibody. Recombinant Human IL-1 RII (Catalog # 263-2R) inhibits Recombinant Human IL-1 beta /IL-1F2 (Catalog # 201-LB) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL-1 beta /IL-1F2 (50 pg/mL) activity elicited by Recombinant Human IL-1 RII (2 µg/mL) is neutralized (green line) by increasing concentrations of Human IL-1 RII Monoclonal Antibody (Catalog # MAB663). The ND50 is typically 5-20 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-1 RII
Two distinct types of receptors that bind the pleiotropic cytokines IL-1 alpha and IL-1 beta have been described. The IL-1 receptor type I is an 80 kDa transmembrane protein that is expressed predominantly by T cells, fibroblasts, and endothelial cells. IL-1 receptor type II is a 68 kDa transmembrane protein found on B lymphocytes, neutrophils, monocytes, large granular leukocytes, and endothelial cells. Both receptors are members of the immunoglobulin superfamily and show approximately 28% sequence similarity in their extracellular domains. The two receptor types do not heterodimerize in a receptor complex. An IL-1 receptor accessory protein that can heterodimerize with the type I receptor in the presence of IL-1 alpha or IL-1 beta, but not IL-1ra, was identified (1). This type I receptor complex appears to mediate all the known IL-1 biological responses. The receptor type II has a short cytoplasmic domain and does not transduce IL-1 signals. In addition to the membrane-bound form of IL-1 RII, a naturally-occurring soluble form of IL-1 RII has been described. It has been suggested that the type II receptor, either as the membrane-bound or as the soluble form, serves as a decoy for IL-1 and inhibits IL-1 action by blocking the binding of IL-1 to the signaling type I receptor complex. Recombinant IL-1 soluble receptor type II is a potent antagonist of IL-1 action.
Citation for Human IL-1 RII Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production.
Authors: Emsley HC, Smith CJ, Gavin CM
BMC Neurol, 2007;7(0):5.
Sample Types: Plasma
Applications: ELISA Development
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human IL-1 RII Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human IL-1 RII Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
MAB663 was used as the capture and AF263 was used as the detection antibody for the sandwich ELISA for sIL-1R2. The immunoassay standard was 263-2R. Assay had sensitivity of ~10pg/ml.